AGC to manufacture Takara Bio's COVID-19 vaccine

By The Science Advisory Board staff writers

May 21, 2020 -- In the fight against COVID-19, AGC Biologics, a contract development and manufacturing organization, is partnering with Takara Bio to manufacture plasmid DNA intermediates for a DNA SARS-CoV-2 vaccine, according to the firms.

The vaccine will be developed based on Osaka University and AnGes plasmid DNA products. AGC will bring over 10 years of expertise in plasmid production to the project and will leverage its manufacturing facilities in Asia, Europe, and the U.S.

The companies did not release expected development timelines.

Copyright © 2020
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here